Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 28, 2008
Novartis's Everolimus: On it's way to being a competitor for Wyeth's Torisel.
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal | online.wsj.com
Author: GLG Expert Contributor
It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.
February 27, 2008
Procrit, Aranesp, Epogen: OMG (O my God) now JAMA piles on.
Analysis of: Higher Risks Found for Anemia Drugs | online.wsj.com
Author: GLG Expert Contributor
Meta analysis of multiple papers shows an increased risk of dealth in cancer patients receiving Epo products.
February 26, 2008
CEP-18770 (Cephalon & Cell Therapeutics Europe) an oral proteosome inhibitor: Millenium beware
Analysis of: CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
IF this agent works it is ORAL and will certainly be more acceptable to patients than the IV Velcade.
February 26, 2008
Gene Directed Therapy: I told you so!! Roche Holding on the right track!
Analysis of: Study: More Complexity In Tailoring Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!
February 25, 2008
Gardasil: Cervical Cancer Vaccine for Boys?? Can you say disingenuous?
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Expert Contributor
Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.
February 25, 2008
Avastin Approved in Breast Cancer: the correct thing was done
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: GLG Expert Contributor
Avastin will be used in the therapy of "advanced" metastatic breast cancer, despite controversial data. In a disease with multiple options and a variable course it is virtually impossible to prove improved survival!!
February 22, 2008
Nexavar (Onyx & Bayer): down & out???
Analysis of: Onyx's Double Dose of Trouble | www.fool.com
Author: GLG Expert Contributor
The Nexavar lung cancer trial was terminated by the data monitoring committee PLUS it caused increased deaths in the squamous cell subgroup. Future in lung cancer?? PLUS: recent info also has shown cardiac events in Nexavar making it a potential loser in the race for kidney cancer dollar.
February 21, 2008
Treanda: A winner for Cephalon in Low grade non-Hodgkin's lymphoma (NHL) AND chronic lymphatic leukemia (CLL).
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: GLG Expert Contributor
The FDA will be deciding on Treanda in CLL next month and with a litttle luck NHL in the fall of this year
February 21, 2008
Avastin (Genentech): Approval in breast cancer? It would be the correct thing to do!
Analysis of: Genentech has billions at stake in FDA battle | sanfrancisco.bizjournals.com
Author: GLG Expert Contributor
Genentech has it's fingers crossed Re: approval or rejection of Avastin in breast cancer. If rejected it will lose it's compendia listing also adversely effecting insurance reimbursement.
February 20, 2008
Picoplatin (Poniard) in Metastatic Prostate Cancer: Why not?
Analysis of: Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients | www.pipelinereview.com
Author: GLG Expert Contributor
Picoplatin + Taxotere (Sanofi) appears in a Phase I trial, to be better than Taxotere alone in reducing PSA levels in metastatic prostate cancer (MPCA.)      (Comparing historical, not head to head data)

Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 506

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203